Suzhou's PegBio Forms China Diabetes Partnership With Pfizer

PegBio Company, a Suzhou diabetes-focused pharma, partnered with Pfizer to bring a Pfizer clinical-stage type 2 diabetes treatment to China. The candidate seems to be PF-04937319, a glucokinase inhibitor that Pfizer designed to be only partially effective as a way of avoiding the hypoglycemic side effect of other GCK drugs. PF-04937319 has completed a Phase IIa trial in the US. Neither company has issued a press release offering details about the deal, though PegBio did affirm that an agreement had been signed.